Performance of 18f-Fluciclovine PET/MR in the Evaluation of Osseous Metastases From Castration-Resistant Prostate Cancer

European Journal of Nuclear Medicine and Molecular Imaging - Germany
doi 10.1007/s00259-019-04540-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

Journal of the Advanced Practitioner in Oncology
2015English

Update On18F-Fluciclovine PET for Prostate Cancer Imaging

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Treatment of Castration-Resistant Prostate Cancer and Bone Metastases With Radium-223 Dichloride

International Journal of Urological Nursing
UrologyNursingNephrology
2014English

Erratum To: 18f-Fluorocholine PET/CT for Early Response Assessment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2015English

Aggressive Variants of Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Radium-223 for the Treatment of Patients With Castration-Resistant Prostate Cancer With Bone Metastases

Medical Council
2018English

Visceral Disease in Castration-Resistant Prostate Cancer

European Urology
Urology
2014English

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Yearbook of Paediatric Endocrinology
2019English

Pcn346 - Disease Specific Cost Analysis of the Nonmetastatic Castration-Resistant Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer Health States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy